UNI-MED Science / Apomorphine in Parkinson's disease

1. A Brief History of Apomorphine 122. Clinical Pharmacology of Apomorphine 163. Neuroprotective Effects of Apomorphine in Parkinson's Disease 204. Diagnostic Use of Apomorphine in Parkinson's Disease 244.1. Introduction 244.2. Test Performance 244.3. Diagnostic Value 264.4. Challenge Tests: Apomorphine vs. Levodopa 284.5. Summary 295. Apomorphine in the Treatment of Parkinson's Disease 326. Intermittent Subcutaneous Apomorphine Injection 346.1. Indications for Apomorphine Pen Therapy - a Suitable Patient 346.2. The Apomorphine Test 356.3. Use of Domperidone 366.4. Starting Apomorphine Therapy 366.5. Typical Apomorphine Doses 376.6. Effects of Apomorphine Therapy 386.7. Side Effects 416.8. Drug interactions 416.9. Alternative Modes of Administration 416.10. Summary 427. Continuous Dopaminergic Stimulation 448. Continuous Subcutaneous Apomorphine Infusion 488.1. Clinical Experience from Continuous s.c. Apomorphine Infusion 498.2. Dyskinesias and Continuous s.c. Apomorphine Infusion 508.3. Continuous s.c. Apomorphine Infusion and Functional Neurosurgery 568.4. Continuous s.c. Apomorphine Infusion versus Levodopa/Carbidopa Intestinal Gel Infusion 588.5. Continuous s.c. Apomorphine Infusion, Levodopa/ Carbidopa Intestinal Gel Infusion and STN-DBS: the choice of advanced PD therapy 588.6. Alternative Routes of continuous Apomorphine Administration 588.7. Summary 619. Side Effects of Apomorphine Therapy 649.1. Subcutaneous Nodules 649.2. Neuropsychiatric Events 659.3. Nausea 699.4. Orthostatic Hypotension 699.5. Hemolytic Anemia 699.6. Sedation, Somnolence and "Sleep Attacks" 699.7. Impulse Control Disorders and Hypersexuality 709.8. Other Side Effects 709.9. Injectable Apomorphine Safety Database 709.10. Pregnancy and Lactation 719.11. Overdose 719.12. Technical Difficulties 719.13. Summary 7110. Health Economy and Patient-Reported Health Outcomes 7410.1. Health Economy 7410.2. Patient-Reported Health Outcomes 7511. Practical Aspects of Apomorphine Therapy 7811.1.